Literature DB >> 11839850

Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers.

J J Ferreira1, M Galitzky, C Thalamas, M Tiberge, J L Montastruc, C Sampaio, O Rascol.   

Abstract

Somnolence and "sleep attacks" have been reported as an adverse effect of several antiparkinsonian drugs. The authors document, in a placebo-controlled, randomized, double-blind, crossover study performed in 20 healthy volunteers, using the Multiple System Latency Test (MSLT) as primary outcome, that ropinirole reduces time to sleep onset in humans. Ropinirole therapy was not associated with daytime episodes of rapid eyes movement (REM) sleep.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839850     DOI: 10.1212/wnl.58.3.460

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers.

Authors:  E R Samuels; R H Hou; R W Langley; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-06-27       Impact factor: 4.530

2.  Sleepiness and Unintended Sleep in Parkinson's Disease.

Authors:  David B. Rye
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 3.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

4.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

Review 5.  Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?

Authors:  K Ray Chaudhuri; Suvankar Pal; Christine Brefel-Courbon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.

Authors:  Joëlle Micallef; Marc Rey; Alexandre Eusebio; Christine Audebert; Frank Rouby; Elisabeth Jouve; Sophie Tardieu; Oliver Blin
Journal:  Br J Clin Pharmacol       Date:  2008-09-19       Impact factor: 4.335

8.  Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness.

Authors:  Diego A Pizzagalli; A Eden Evins; Erika Cowman Schetter; Michael J Frank; Petra E Pajtas; Diane L Santesso; Melissa Culhane
Journal:  Psychopharmacology (Berl)       Date:  2007-10-02       Impact factor: 4.530

Review 9.  Excessive daytime sleepiness and unintended sleep in Parkinson's disease.

Authors:  David B Rye
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.